Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy.
about
Sources of Heterogeneity in Trials Reporting Hydroxyethyl Starch 130/0.4 or 0.42 Associated Excess Mortality in Septic Patients: A Systematic Review and Meta-regressionRe-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients - a multidisciplinary statementConcerns about renal safety of HES 130.Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial.Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine.Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality.Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review.Effect of hydroxyethyl starch on postoperative kidney function in patients having noncardiac surgery.Hydroxyethyl starch versus other fluids for non-septic patients in the intensive care unit: a meta-analysis of randomized controlled trialsFluid challenges in intensive care: the FENICE study: A global inception cohort study.Intravascular volume therapy in adults: Guidelines from the Association of the Scientific Medical Societies in Germany.Fluid replacement with hydroxyethyl starch in critical care--a reassessmentRelative survival benefit and morbidity with fluids in severe sepsis - a network meta-analysis of alternative therapies.Clinical controversies in the management of critically ill patients with severe sepsis: resuscitation fluids and glucose control.What's new in organ donation: better care of the dead for the living.Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition.Critical care medicine 2013: a review and prospectReporting bias in trials of volume resuscitation with hydroxyethyl starch.Controversies in fluid therapy: Type, dose and toxicity.Hydroxyethyl starch: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use.Hydroxyethyl starch and granulocyte transfusions: considerations of utility and toxicity profile for patients and donors.Fluid resuscitation in acute medicine: what is the current situation?Scandinavian clinical practice guideline on choice of fluid in resuscitation of critically ill patients with acute circulatory failure.The crystalloid-colloid debate: Consequences of resuscitation fluid selection in veterinary critical care.Controversies in the use of hydroxyethyl starch solutions in small animal emergency and critical care.Effect of perioperative crystalloid or colloid fluid therapy on hemorrhage, coagulation competence, and outcome: A systematic review and stratified meta-analysis.Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity.Investigation on the Interaction of Hydroxyethyl Starch 130/0.4 (Voluven) and Serum Albumin for Pharmacokinetic and Toxicological Implications.Retrospective cohort study on the incidence of acute kidney injury and death following hydroxyethyl starch (HES 10% 250/0.5/5:1) administration in dogs (2007-2010).What is the impact of the fluid challenge technique on diagnosis of fluid responsiveness? A systematic review and meta-analysis.Duration of hemodynamic effects of crystalloids in patients with circulatory shock after initial resuscitation.Rapid exacerbation of renal function after administration of hydroxyethyl starch in a dog.Debate on HES safety is important, but must be based on factsHydroxyethyl starch: putting patient safety first.Risks of hydroxyethyl starch 130/0.4 in cardiac surgery."Colloid twice daily" is not fluid resuscitation! Inappropriate inclusion of clinical trials in meta-analyses may distract from gaps in evidence.Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate.Effects of hydroxyethyl starch 130/0.42 vs. Ringer's acetate on cytokine levels in severe sepsis.What's new in the controversy on the renal/tissue toxicity of starch solutions?Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial.
P2860
Q26796519-93E2C5A9-841B-4181-A3F6-4D75C580A183Q28658225-93C8FA05-78E2-4FD2-BF9F-0FF48DDCAE3FQ33754625-64110096-7BA2-4CEF-B9E6-3559A66C4F9CQ33754763-B4803137-487F-478A-A20F-576836DA970DQ33843623-4D6AE2F3-8B96-4E4D-A9A5-61B08785922AQ33930693-4A60CEA4-D41B-4D00-9C56-7336AE1C0161Q34386552-9650C3BF-77F2-461A-B717-152B8B53156EQ35318655-DE3E56FC-BA64-4D77-865F-363599416F56Q35504839-77A5510F-FB9D-4215-B983-AB60380EAF93Q35998723-64D56D60-0064-4CDF-A341-A914F03E5268Q36961877-7A3BF112-0543-498A-880E-A6A161BBCF06Q37035700-63A415DC-9749-4F35-9F5F-0B3F247F6C1FQ37376423-73D4E89B-CBD2-4AA0-893C-3F395FCDD20CQ37563000-0FCE4292-C48B-4311-B1C7-D13FC5B6DDACQ38126338-0E821F2F-8B32-4DEC-ABB2-5D3C3D2AFDBCQ38171279-AA3AD773-8219-4A6B-94C0-A6F8650C4192Q38177276-59F5D782-BEBA-4BD8-B38B-084725637178Q38193389-229EFDF0-F578-4494-AB5C-AB7012CEFD65Q38212251-A3F8A875-C131-45F3-BBA0-EF9EF298621CQ38243449-718EFEAF-D63D-40BE-B317-5C033521845DQ38260203-C9D249A6-18D8-4B68-8603-28DA0C961AB2Q38263452-5345EF49-2332-4BB7-8558-43C56E291391Q38264372-A9471C2D-DC01-45CC-B54E-47FE358C4DCAQ38328615-794D3630-0E99-4303-A06B-A9F20C78C152Q38345631-794E8B47-D0F1-427B-80B1-E3A8C5AED258Q38919734-2D9A5BF0-751E-487D-A072-B84EF1BF47F7Q38947834-68A08B6E-8FC4-4781-9BAC-44714D73D43CQ40125393-F9AA7535-C7AE-485A-A595-EF976F1C622FQ41110540-BD1D3F3F-9886-4B3C-888A-9FBEB29FC6A9Q41248330-C2BCA460-6F01-491F-BCD1-47A7B03F33D3Q41575409-633530CC-7EFE-46EB-9133-13CA39613126Q42125704-CF6829A6-7B17-4799-8FB9-CFF149603A95Q42590139-B7251601-B503-4C0A-B309-CAD746C62385Q44796329-F5D8078F-D9D5-476C-AFFB-ED6FC3FC574CQ45297080-A86E98C8-B4AB-4995-B6AA-CAA8D7769B1EQ45348503-75456654-163D-4F20-A100-B6F7107B0099Q46823402-006BF50C-2449-4FCE-809B-A8CF1B60F566Q48218978-FC100839-D582-4716-B82A-A0DBE7B43CD4Q49094040-8E643736-DF6F-4E30-AF5C-E0925522D54DQ50485301-9A03718C-0DAA-49ED-B6CE-7F4A77908F8F
P2860
Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Fluid resuscitation with 6 % h ...... ith renal replacement therapy.
@en
type
label
Fluid resuscitation with 6 % h ...... ith renal replacement therapy.
@en
prefLabel
Fluid resuscitation with 6 % h ...... ith renal replacement therapy.
@en
P2093
P2860
P1476
Fluid resuscitation with 6 % h ...... ith renal replacement therapy.
@en
P2093
CHEST Management Committee
David J Gattas
John Myburgh
Simon Finfer
P2860
P2888
P304
P356
10.1007/S00134-013-2840-0
P577
2013-02-14T00:00:00Z